Global Cardiac Resynchronization Therapy Markets Analysis & Forecasts Report 2017-2021 & 2022-2030 Featuring Abbott, Boston Scientific, Medtronic, Biotronik Se & Co, & Microport Scientific
04 mars 2022 04h48 HE
|
Research and Markets
Dublin, March 04, 2022 (GLOBE NEWSWIRE) -- The "Cardiac Resynchronization Therapy Market Size, Share & Trends Analysis Report by Product (CRT-defibrillator, CRT-pacemaker), by End User...
Global Precision Cardiology Industry 2021-2031: Focus on Offering, Sample, Technology, Application, End-user, and Region
28 févr. 2022 06h28 HE
|
Research and Markets
Dublin, Feb. 28, 2022 (GLOBE NEWSWIRE) -- The "Precision Cardiology Market - A Global and Regional Analysis: Focus on Offering, Sample, Technology, Application, End User, and Region - Analysis and...
Global Cardiology IT Workflow Solutions Market 2022-2026: A $1.3 Billion Opportunity Assessment
23 févr. 2022 04h53 HE
|
Research and Markets
Dublin, Feb. 23, 2022 (GLOBE NEWSWIRE) -- The "Cardiology IT Workflow Solutions - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Wide...
Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health
31 janv. 2022 07h00 HE
|
Madrigal Pharmaceuticals, Inc.
Primary and key secondary endpoints from the double-blind placebo-controlled 969-patient MAESTRO-NAFLD-1 safety study were achieved and demonstrate that resmetirom: Was safe and well-tolerated at 80...
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st
30 janv. 2022 16h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Jan. 30, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases,...
Demand: Global Computer-aided Drug Discovery Market Estimated to Surpass $7,914.2 Million by 2028, and Grow at a CAGR of 15.0% during the Forecast Period [224-Pages] | Divulge By Research Dive
25 janv. 2022 09h00 HE
|
Research Dive
New York, USA, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Research Dive states that the global computer-aided drug discovery market is estimated to garner a revenue of $7,914.2 million by 2028, and rise at...
Casana Closes $30 Million Series B Funding to Accelerate Development of Novel Effortless Home Health Monitoring
21 janv. 2022 12h15 HE
|
Casana Care, Inc.
ROCHESTER, N.Y., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Casana, a healthcare technology firm that is reinventing in-home health monitoring, announced today that it has raised $30 million in Series B...
Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer
10 janv. 2022 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases,...
Opportunities: Computer-aided Drug Discovery Market Expected to Gather a Revenue of $7,914.2 Million by 2028, Growing at a CAGR of 15% from 2021 to 2028 [224-Pages] | Business study by Research Dive
04 janv. 2022 09h00 HE
|
Research Dive
New York, USA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Research Dive has added a new report to its offering titled, “Computer-aided Drug Discovery Market by Type (Structure-based Drug Design (SBDD),...
Esperion Appoints Benjamin O. Looker as General Counsel
04 janv. 2022 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced the appointment of Benjamin O. Looker as general counsel as of January 1, 2022. Mr. Looker will serve as...